Stocktoria
REGENTIS BIOMATERIALS LTD. RGNT
NYSE American · XASE · stock
REGENTIS BIOMATERIALS LTD. financials (annual, from 10-K)
Bars are annual figures from 2024 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 |
|---|---|---|
| Operating income | -$7.0M | $932,000 |
| Net income | -$13.6M | $4.8M |
| EPS (diluted) | $-24.16 | $1.72 |
| Operating cash flow | -$1.4M | -$641,000 |
| Cash & equivalents | $7.4M | — |
| Total assets | $7.6M | $482,000 |
| Total liabilities | $2.9M | $6.5M |
| Shareholders' equity | $4.7M | -$41.1M |
Growth · year-over-year
| Metric | FY2025 | FY2024 |
|---|---|---|
| Net income growth | -384.3% | — |
| EPS growth | -1504.7% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001912966 · US · as of 2025-12-31. facts plus Stocktoria's own computed scores — not investment advice.